Search

Displaying results 3481 - 3490 of 8196 in total
  1. Drug

    Nandrolone phenpropionate

    go.drugbank.com/drugs/DB00984
    ApprovedIllicit

    C18 steroid with androgenic and anabolic properties. It is generally prepared from alkyl ethers of estradiol to resemble testosterone but less one carbon at the 19 position. It is a schedule III drug in the U.S.

  2. Drug

    EP-1043

    go.drugbank.com/drugs/DB06118
    Experimental

    EP-1043 is an epitope-based recombinant protein vaccine designed to induce HIV-1 specific helper T-lymphocyte (HTL) responses.

  3. Drug

    Eptinezumab

    go.drugbank.com/drugs/DB14040
    ApprovedInvestigational

    Eptinezumab is a fully-humanized IgG1 antibody manufactured using yeast (Pichia pastoris) and developed by Lundbeck Seattle Biopharmaceuticals. Eptinezumab has been specifically designed to bind to both alpha and beta forms of the human ...

  4. Drug

    Etanercept

    go.drugbank.com/drugs/DB00005
    ApprovedInvestigational

    Dimeric fusion protein consisting of the extracellular ligand-binding portion of the human 75 kilodalton (p75) tumor necrosis factor receptor (TNFR) linked to the Fc portion of human IgG1. The Fc component of etanercept contains the CH2 ...

  5. Drug

    Propacetamol

    go.drugbank.com/drugs/DB09288
    Investigational

    Propacetamol is a non-opioid analgesic devoid of the major contraindications. It is a derivative of acetaminophen, or paracetamol, with the molecular formula glycine, N, N-diethyl-,4-(acetylamino)phenyl ester. Propacetamol is a parentera...

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A Inducers
  6. Drug

    Trifarotene

    go.drugbank.com/drugs/DB12808
    ApprovedInvestigational

    [A187081] Trifarotene is considered the first of the "fourth-generation" retinoids due to its uniquely selective activity - this selectivity appears to confer improved efficacy and reduced side effects

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2B6 Substrates
  7. Drug

    Fibrinolysin

    go.drugbank.com/drugs/DB05254
    Investigational

    The light chain has a molecular weight of approximately 27,000 Da and contains the active center of Fibrinolysin; the heavy chain has a molecular weight of approximately 57,000 Da. … The combination is available as ointment containing 1 BU (Biological Unit) Fibrinolysin and 666 BUs desoxyribonuclease per gram.

  8. Drug

    Flecainide

    go.drugbank.com/drugs/DB01195
    ApprovedInvestigationalWithdrawn

    [A186880] Flecainide’s development began in 1966 and was first synthesized in 1972 as an attempt to generate new anesthetics.

    Categories: P-glycoprotein substrates, Cytochrome P-450 Substrates
  9. Drug

    Acrivastine

    go.drugbank.com/drugs/DB09488
    Approved

    Acrivastine is currently available in combination with pseudoephedrine as the FDA-approved product Semprex-D. … As an H1 receptor antagonist, it functions by blocking the action of histamine at this receptor thereby preventing the symptoms associated with histamine release such as pruritis, vasodilation, hypotension

    Mixtures: Semprex-D, Semprex D
  10. Drug

    Denosumab

    go.drugbank.com/drugs/DB06643
    ApprovedInvestigational

    [A263066] An Denosumab biosimilar, Jubbonti, was approved for Health Canada in February 2024.[L52083]. … Jubbonti® (denosumab-bbdz)[L53058]—were approved by the FDA in March 2024 for all indications of the reference products Xgeva® and Prolia®; Both biosimilars also received marketing authorization in the EU